Two high-flying ASX shares: One upgraded, one downgraded

One of these high-flying shares could keep rising and one could fall.

| More on:
A businesswoman on the phone is shocked as she looks at her watch, she's running out of time.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Two ASX shares that have made their shareholders smile this year are DroneShield Ltd (ASX: DRO) and Telix Pharmaceuticals Ltd (ASX: TLX).

Since the start of the year, their shares have risen by approximately 120% and 50%, respectively. As a comparison, the Australian share market is up around 0.5% over the same period.

However, one leading broker believes that one of these high-flying ASX shares could have peaked for the time being. This has led to its analysts downgrading its shares to a hold rating.

The good news for the other share is that its analysts have gone the other way with it. Despite its very strong gains, the broker has upgraded it to a buy rating from hold this week.

Which ASX shares have been downgraded?

According to a note out of Bell Potter, its analysts have downgraded Telix Pharmaceuticals' shares to a hold rating with a $14.50 price target. This implies a potential downside of 5% from its current share price of $15.24.

While the broker is a big fan of the radiopharmaceuticals company, it feels that its valuation is full. Particularly given that there are significant clinical risks on the horizon. Commenting on the downgrade, its analysts said:

The short term outlook for revenue growth from the diagnostic assets remains attractive, nevertheless the major inflection points for TLX591 in the treatment of prostate cancer are close and carry significant clinical risk. We expect a readout on the important efficacy measure of progression free survival within the next 2 to 3 months. A poor clinical readout has the potential to materially impact the share price and accordingly we downgrade from Buy to Hold on the basis of valuation, noting this is the first recommendation downgrade since our initiation coverage in 2021. PT remains $14.50.

DroneShield upgraded

On the same day, the broker upgraded this counter drone technology company's shares to a buy rating with a $1.00 price target. Based on the current DroneShield share price of 83 cents, this implies a potential upside of 20% for investors.

The broker made the move following a pullback in its share price in response to a recent capital raising. It feels this funding leaves DroneShield well-positioned to capture the increasing demand for its technology. It explains:

DroneShield is now well placed to capitalise on the growing demand for C-UAS solutions in response to current global tensions and the evolution of modern warfare. Our forecasts likely remain conservative relative to the current sales pipeline, however the risk of government delay remains prevalent in contracts of this nature. With the SP now trading near the issue price, we upgrade our recommendation to BUY.

Motley Fool contributor James Mickleboro has positions in Telix Pharmaceuticals. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended DroneShield and Telix Pharmaceuticals. The Motley Fool Australia has recommended Telix Pharmaceuticals. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Growth Shares

Two excited woman pointing out a bargain opportunity on a laptop.
Growth Shares

2 ASX growth shares with rapidly-rising dividends to buy now

Rapidly growing businesses are appealing for multiple reasons.

Read more »

a man in a green and gold Australian athletic kit roars ecstatically with a wide open mouth while his hands are clenched and raised as a shower of gold confetti falls in the sky around him.
Growth Shares

3 amazing Australian stocks to buy and hold until 2030

Analysts think these shares could be high-quality options for investors looking for long term picks.

Read more »

A man has a surprised and relieved expression on his face. as he raises his hands up to his face in response to the high fluctuations in the Galileo share price today
Growth Shares

Why these ASX 200 growth shares could rise 40% in 12 months

Analysts are tipping these shares to deliver big returns over the next 12 months.

Read more »

A woman makes the task of vacuuming fun, leaping while she pretends it is an air guitar.
Opinions

Opinion: This is one of the best ASX growth shares to own for the next 5 years

This stock is rapidly growing, and I’m excited about it.

Read more »

Three happy office workers cheer as they read about good financial news on a laptop.
Growth Shares

Buy Xero and this ASX 200 growth share in February

Analysts have good things to say about these growing companies.

Read more »

happy investor, share price rise, increase, up
Growth Shares

Buy these ASX growth shares with $3,000 in February

Analysts think these growth shares could be great options for investors with money to put into the share market.

Read more »

Man holding out Australian dollar notes, symbolising dividends.
Growth Shares

2 no-brainer ASX All Ords shares to buy with $2,000

Analysts have good things to say about these stocks. Let's see why they are so bullish.

Read more »

Two men look excited on the trading floor as they hold telephones to their ears and one points upwards.
Growth Shares

Where to invest $1,000 into ASX 200 stocks in February

Analysts think these shares would be great options for Aussie investors next month.

Read more »